SCHEMBL24378129

SCHEMBL24378129

COC(=O)c1ccc2c(c1)OC(C(N)=O)CN2

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SIRT1 Q96EB6 1/20 0.44
ALOX5 P09917 1/20 0.41
HPGD P15428 4/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
CYSLTR1 Q9Y271 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
HSD17B10 Q99714 4/20 0.39
MAPT P10636 4/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
CASP7 P55210 1/20 0.39
ATM Q13315 1/20 0.39
CA12 O43570 2/20 0.39
CA9 Q16790 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24378128 0.90 ALOX5 (0.47) SIRT1ALOX5HPGDKMT2AMEN1
SCHEMBL18581073 0.84 ALOX5 (0.38) ALOX5HPGDKMT2AMEN1CYSLTR1
SCHEMBL18584331 0.79 ALOX5 (0.47) ALOX5HPGDKMT2AMEN1CYSLTR1
SCHEMBL30874435 0.76 ALOX5 (0.41) ALOX5HPGDKMT2AMEN1NPC1
SCHEMBL22226392 0.76 ALOX5 (0.41) ALOX5HPGDKMT2AMEN1NPC1
SCHEMBL24100117 0.76 ALOX5 (0.41) ALOX5HPGDKMT2AMEN1NPC1
SCHEMBL24377973 0.76 HPGD (0.39) SIRT1ALOX5HPGDKMT2AMEN1
SCHEMBL23013290 0.76 ADAMTS5 (0.40) SIRT1HPGDKMT2ACYSLTR1HSD17B10
SCHEMBL29481459 0.76 ADAMTS5 (0.40) SIRT1HPGDKMT2ACYSLTR1HSD17B10
SCHEMBL18581139 0.74 ALOX5 (0.43) ALOX5HPGDKMT2AMEN1CYSLTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER CKMT1A; CKMT1B, PHKG1, PCK1 SIRT1 935/4885ALOX5 3231/4885HPGD 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.